Modelling the cost-effectiveness of tofacitinib for the treatment of rheumatoid arthritis in the United States.

Lindsay ClaxtonMatthew TaylorRobert A GerberDavid GrubenDermot MoynaghAmitabh SinghGene V Wallenstein

Published in: Current medical research and opinion (2018)

Tofacitinib as a second-line therapy following methotrexate failure and as a third-line therapy following a biologic failure produces lower costs and improved quality of life compared with the current pathway of care.

Keyphrases

rheumatoid arthritis
disease activity
healthcare
ankylosing spondylitis
palliative care
interstitial lung disease
high dose
quality improvement
ulcerative colitis
systemic lupus erythematosus
combination therapy
low dose
pain management
replacement therapy
idiopathic pulmonary fibrosis